JonesTrading analyst Soumit Roy has maintained their bullish stance on INAB stock, giving a Buy rating on May 8.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Soumit Roy has given his Buy rating due to a combination of factors that highlight the promising potential of IN8bio’s innovative therapies. The recent preclinical data presented by IN8bio at the ASGCT conference demonstrated significant efficacy of their CD19 targeting γδ TCE, INB-619, in depleting B cells in lupus patient blood samples. This is a crucial development, as the data showed approximately 75-90% B-cell depletion within ten days, along with an increase in γδ T cell expansion and lower levels of pro-inflammatory cytokines, suggesting a favorable safety profile for autoimmune disease treatments.
Furthermore, the company’s management is actively seeking partnerships to advance this promising program, which adds to the positive outlook. While the focus remains on their leukemia program, with anticipated updates in the second half of 2025, the potential for collaboration and the promising preclinical results contribute to the Buy rating. The combination of these strategic initiatives and scientific advancements positions IN8bio as a compelling investment opportunity.
In another report released on May 8, H.C. Wainwright also maintained a Buy rating on the stock with a $6.00 price target.